Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
Merck.com••business
Key Points:
- Merck has reached an agreement with the Trump administration to make its prescription medicines more accessible and affordable for Americans, addressing global drug pricing imbalances that have burdened the U.S. healthcare system.
- The company will offer key products like JANUVIA, JANUMET, and JANUMET XR at approximately 70% off the current list price through a direct-to-patient program for eligible patients, with plans to include enlicitide decanoate pending FDA approval.
- Enlicitide, a novel oral drug candidate designed to lower LDL cholesterol and combat cardiovascular disease, aims to provide an affordable alternative to injectable PCSK9 inhibitors if approved.
- Merck has agreed with the U.S. Department of Commerce to delay Section 232 tariffs
